A mistrial in the most recent Vioxx case. Some say this is not a good sign for Merck:
Legal analysts had predicted that the case would be decided in Merck’s favor because the patient in question had taken Vioxx for barely a month. The mistrial points to some jurors’ willingness to trace serious health problems to even short-term use of the drug, raising concerns for Merck as it faces thousands of similar lawsuits.
